Effect Of Amitriptyline and Fluoxetine in Patients Presenting with Mixed Anxiety and Depression: Comparative Study
Authors/Creators
- 1. Senior Resident, Department of Psychiatry, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, UP, India
- 2. Professor, Department of Psychiatry, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, UP, India
- 3. Assistant Professor, Department of Psychiatry, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, UP, India
Description
Aim: Comparative study of efficacy of amitriptyline and fluoxetine in patients presenting with mixed anxiety and depression. Materials and Methods: This comparative study was carried out in the Department of Psychiatry, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, UP, India, for 15 months. Fifty-eight patients (25 male and 25 female) from 3 sites were enrolled in the study. Ages ranged from 20 to 60 (mean = 41.11 k 9.11) years. Results: 50 patients were taken in the study and were divided into two groups with each group holding 25 patients. Two drugs namely fluoxetine and amitriptyline taken in study to determine their effects on two groups (25 on fluoxetine and 25 on amitriptyline) completed. As noted, fluoxetine was given at a fixed dose of 20 mg/day for the duration of the study. The dose of amitriptyline was gradually increased to 150 mg over the first 2 weeks. By week 6, 12 (55%) of the patients on amitriptyline were taking 200 mg/day and the remainder 150 mg/day. Compliance as reported to the treating physician varied from 85-100% of patients at any one visit. Approximately half of the patients in each treatment group (fluoxetine 16/25, amitriptyline 17/25) were on concomitant non-psychotropic medications at the start of the trial (p>O. 1, chi square test). Both treatments produced a statistically significant reduction in HDRS score from baseline as assessed by the repeated measures analysis of variance (p<O.O001). Conclusion: We concluded that the fluoxetine 20 mg/day is effective in the acute treatment of patients with moderately severe depression. It appears to be well tolerated, with a different side-effect profile from that of amitriptyline.
Abstract (English)
Aim: Comparative study of efficacy of amitriptyline and fluoxetine in patients presenting with mixed anxiety and depression. Materials and Methods: This comparative study was carried out in the Department of Psychiatry, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, UP, India, for 15 months. Fifty-eight patients (25 male and 25 female) from 3 sites were enrolled in the study. Ages ranged from 20 to 60 (mean = 41.11 k 9.11) years. Results: 50 patients were taken in the study and were divided into two groups with each group holding 25 patients. Two drugs namely fluoxetine and amitriptyline taken in study to determine their effects on two groups (25 on fluoxetine and 25 on amitriptyline) completed. As noted, fluoxetine was given at a fixed dose of 20 mg/day for the duration of the study. The dose of amitriptyline was gradually increased to 150 mg over the first 2 weeks. By week 6, 12 (55%) of the patients on amitriptyline were taking 200 mg/day and the remainder 150 mg/day. Compliance as reported to the treating physician varied from 85-100% of patients at any one visit. Approximately half of the patients in each treatment group (fluoxetine 16/25, amitriptyline 17/25) were on concomitant non-psychotropic medications at the start of the trial (p>O. 1, chi square test). Both treatments produced a statistically significant reduction in HDRS score from baseline as assessed by the repeated measures analysis of variance (p<O.O001). Conclusion: We concluded that the fluoxetine 20 mg/day is effective in the acute treatment of patients with moderately severe depression. It appears to be well tolerated, with a different side-effect profile from that of amitriptyline.
Files
IJTPR,Vol12,Issue2,Article8.pdf
Files
(187.5 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:5ed60b5a23431b0433475538397a102b
|
187.5 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-01-10
Software
References
- 1. Mokdad AH Forouzanfar MH Daoud F et al.Global burden of diseases, injuries, and risk factors for young people's health during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.Lancet. 2016; 387: 2383-2401 2. Sadler K Vizard T Ford T et al.Mental health of children and young people in England, 2017: summary of key findings.NHS Digital, 2018 https://digital.nhs.uk/data-andinformation/publications/statistical/ment al-health-of-children-and-young-peoplein-england/2017/2017Date accessed: March 3, 2020 3. Ryan ND Treatment of depression in children and adolescents. Lancet. 2005; 366: 933-940 4. Thapar A Collishaw S Pine DS Thapar AK Depression in adolescence. Lancet. 2012; 379: 1056-1067 5. Hopkins K Crosland P Elliott N Bewley S Diagnosis and management of depression in children and young people: summary of updated NICE guidance. BMJ. 2015; 350: h824 6. Bachmann CJ Aagaard L Burcu M et al.Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005-2012. Eur Neuropsychopharmacology. 2016; 26: 4 11-419 7. Zhou X Hetrick SE Cuijpers P et al. Comparative efficacy and acceptability of psychotherapies for depression in children and adolescents: a systematic review and network meta-analysis. World Psychiatry. 2015; 14: 207-222 8. Eckshtain D Kuppens S Ugueto A et al. Meta-analysis: 13-year follow-up of psychotherapy effects on youth depression. J Am Acad Child Adolesc Psychiatry. 2020; 59: 45-63 9. Weisz JR Kuppens S Ng MY et al.What five decades of research tells us about the effects of youth psychological therapy: a multilevel meta-analysis and implications for science and practice.Am Psychol. 2017; 72: 79-117 10. Cipriani A Zhou X Del Giovane C et al.Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network metaanalysis.Lancet. 2016; 388: 881-890 11. Vitiello B Davico CTwenty years of progress in paediatric psychopharmacology: accomplishments and unmet needs. Evid Based Ment Health. 2018; 21: e10 12. Locher C Koechlin H Zion SR et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotoninnorepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. JAMA Psychiatry. 2017; 74: 1011-1020 13. Cox GR Callahan P Churchill R et al. psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents. Cochrane Database Syst Rev. 2012; 11CD008324 14. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 1967: 6278.296. 15. Carroll BJ, Feinberg M. Smouse PE. Rawson SG. Greden JF. The Carroll Rating Scale for Depression I. Development. Reliability and Validation. British Journal of Psychiatry 1981; 138: 194-200. 16. Manna V. Martucci N, Agnoli A. Doubleblind controlled study on the clinical efficacy and safety of fluoxetine versus clomipramine in the treatment of major depressive disorders. International Clinical Psychopharmacology 1989: 4 (Supplement 1):8 I -X8. 17. Ginestet D. Alby JM. Besancon G. Carrier G, Cordier B. Degiovanni A, Dufour H. Ferreri M. Leger L. Moron P. Pellet J, Perivier E. Singer L. Utliac G. Fluoxetine in endogenous depression and melancholia versus clomipramine. International Clinical Psychopharmacology 1989:4:37-40. 18. Clark C. Downie CC. A method for the rapid determination of the number of patients to include in a controlled clinical trial. Lancet 1966: 2:1357-1358. 19. Teicher MH. Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry 1990: 147:207-10. 20. Masand P, Gupta S, Dewan M. Suicidal ideation related to fluoxetine treatment. New England Journal of Medicine 1991; 324:420. 21. Beasley CM. Dornseif BE. Bosomworth JC. Sayler ME, Rampey AH, Heiligenstein JH, Thompson VL. Murphy DJ, Marica DN. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. British Medical Journal 199 I; 303:685- 692. 22. Cooper GL. The safety of fluoxetine -an update. British Journal of Psychiatry. 1988; 153:(Supplement 3). 77-86.